Shares of Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) shot up 12.9% during mid-day trading on Wednesday . The stock traded as high as C$1.76 and last traded at C$1.75. 62,156 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 122,649 shares. The stock had previously closed at C$1.55.
Medicenna Therapeutics Price Performance
The firm has a market capitalization of C$135.80 million, a P/E ratio of -8.48 and a beta of 1.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.65 and a current ratio of 5.00. The firm has a 50-day moving average of C$1.49 and a 200-day moving average of C$0.80.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Read More
- Five stocks we like better than Medicenna Therapeutics
- How to Start Investing in Real Estate
- Hasbro’s Management Made All the Right Calls This Quarter
- What Are Dividend Contenders? Investing in Dividend Contenders
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Overbought Stocks Explained: Should You Trade Them?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
